Proton Conduction in Sulfonated Organic-Inorganic Hybrid Monoliths with Hierarchical Pore Structure.

Porous organic-inorganic hybrid monoliths with hierarchical porosity exhibiting macro- and mesopores are prepared via sol-gel process under variation of the mesopore size. Organic moieties in the pore walls are incorporated by substituting up to 10% of the silicon precursor tetramethylorthosilicate with bisilylated benzene molecules. After functionalization with sulfonic acid groups, the resulting sulfonated hybrid monoliths featuring a bimodal pore structure are investigated regarding proton conduction depending on temperature and relative humidity.

Three Series of Sulfo-Functionalized Mixed-Linker CAU-10 Analogues: Sorption Properties, Proton Conductivity, and Catalytic Activity.

Ten mixed-linker metal-organic frameworks [Al(OH)(m-BDC-X)(1-y)(m-BDC-SO3H)y] (H2BDC = 1,3-benzenedicarboxylic acid; X = H, NO2, OH) exhibiting the CAU-10-type structure were synthesized. The compounds can be grouped into three series according to the combination of ligands employed. The three series of compounds were obtained by employing different ratios of m-H2 BDC-X and m-H2BDC-SO3Li.

High-throughput microwave-assisted discovery of new metal phosphonates.

A systematic study was carried out to investigate the influence of linker geometry, metal ionic radius as well as the nature of the counter ions on the structure formation of metal tetraphosphonates. Two tetraphosphonic acids p- and m-(H2O3PCH2)2N-CH2-C6H4-CH2-N(CH2PO3H2)2, six metal ions (Ca(2+), Mn(2+), Co(2+), Ni(2+), Zn(2+), and Cd(2+)) and two different counter ions (Cl(-) and NO3(-)) were employed using high throughput methods. Microwave (MW)-assisted heating led to the discovery of ten new metal-phosphonates which crystallize in three different crystal structures.

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

Background: Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid inhibits osteoclastic bone resorption, is effective in maintaining bone health, and may therefore be beneficial in this setting.

Methods: Overall, 602 postmenopausal women with early, hormone receptor-positive BC receiving adjuvant letrozole were randomized (301 each group) to receive upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months) for 5 years.

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

Purpose: Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in postmenopausal women with early-stage breast cancer. The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss.

Patients And Methods: Patients receiving adjuvant letrozole were randomly assigned to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months).